Design, identification, optimisation and validation of selective casein kinase II(CK2) modulator
- At: Seville (Spain) (2022)
- Type: Poster
- Poster code: CBS-010
- By: SHOEMAKE, Claire ()
- Co-author(s): Ms Oksana Friggieri, Pharmacy
Dr Claire Shoemake, Senior Lecturer
The CK2 receptor has been acknowledged as a key contributor to carcinogenesis and has been identified as a druggable target in oncology because its inhibition slows down cellular metabolism. GO289 has been identified as a promising molecule for the mitigation of phosphorylation of circadian proteins and proliferation of malignant cells through CK2 .. The access to the whole abstract and if available the presentation file is available to FIP members and to congress participants of that specific congress.